Discovery of 3,4-dihydropyrimido[4,5-<em>d</em>]pyrimidin-2(1<em>H</em>)-one and 3,4-dihydropyrido[2,3-<em>d</em>]pyrimidin-2(1<em>H</em>)-one derivatives as novel ENPP1 inhibitors

Publication date: 1 November 2022Source: Bioorganic & Medicinal Chemistry Letters, Volume 75Author(s): Jae Eun Jung, Yunseong Jang, Hee Jin Jeong, Sung Joon Kim, Kichul Park, Do Hee Oh, Ahran Yu, Chan Sun Park, Seo-Jung Han

Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of ‘first-in-kind’ inhibitors of serine/threonine kinase25

Publication date: 1 November 2022Source: Bioorganic & Medicinal Chemistry Letters, Volume 75Author(s): Scarlett Kiyeleko, Sofiane Hocine, Giséle Mautino, Mélaine Kuenemann, Agata Nawrotek, Linda Miallau, Laurent-Michel Vuillard, Olivier Mirguet, Andras…

The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer

Publication date: 1 November 2022Source: Bioorganic & Medicinal Chemistry Letters, Volume 75Author(s): Chetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, David Frennesson, Peiying Liu, Audris Huang, John Tokarski, Aberra Fura, Thomas Spires, Joh…